The phase IIb PADOVA study, evaluating Roche's prasinezumab in people with early-stage Parkinson's disease, misses the primary endpoint.

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.

The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian...

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYLYNK─001 trial evaluating Keytruda (pembrolizumab) plus...

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYLYNK─001 trial evaluating Keytruda (pembrolizumab) plus...

Brain imaging shows that dancing in people with Parkinson's disease can help reduce depression symptoms.

Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study published in the Journal...

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate...